deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT04284488

Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors

A Phase Ib/II Clinical Study to Evaluate the Efficacy and Safety of APG-1387 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Sponsor: Ascentage Pharma Group Inc.

Conditions Advanced Solid Tumor
Interventions APG-1387 for Injection Toripalimab
Updated 12 times since 2020 Last updated: Jan 7, 2026 Started: Apr 10, 2020 Primary completion: Nov 30, 2024 Completion: Nov 30, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Company Strategy

Other terminated trials from Ascentage Pharma Group Inc.

More terminations from Ascentage Pharma Group Inc.

Other Advanced Solid Tumor trials with similar outcome

Browse all Advanced Solid Tumor trials

Listed as NCT04284488, this PHASE1/PHASE2 trial focuses on Advanced Solid Tumor and remains terminated or withdrawn. Sponsored by Ascentage Pharma Group Inc., it has been updated 12 times since 2020, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Mar 2020 – ~Jun 2020 · 3 months · monthly snapshot~Jun 2020 – ~Jan 2021 · 7 months · monthly snapshotRecruiting~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Mar 2022 · 6 months · monthly snapshot~Mar 2022 – ~Nov 2022 · 8 months · monthly snapshotRecruiting~Nov 2022 – ~Nov 2023 · 12 months · monthly snapshotRecruiting~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2025 · 14 months · monthly snapshotRecruiting~Nov 2025 – ~Feb 2026 · 3 months · monthly snapshot~Feb 2026 – present · 7 months · monthly snapshotTerminated

Change History

12 versions recorded

  1. Feb 2026 — Present [monthly]

    Terminated PHASE1/PHASE2

    Status: Unknown → Terminated

  2. Nov 2025 — Feb 2026 [monthly]

    Unknown PHASE1/PHASE2

    Status: Recruiting → Unknown

  3. Sep 2024 — Nov 2025 [monthly]

    Recruiting PHASE1/PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  5. Nov 2023 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

▶ Show 7 earlier versions

  1. Nov 2022 — Nov 2023 [monthly]

    Recruiting PHASE1_PHASE2

  2. Mar 2022 — Nov 2022 [monthly]

    Recruiting PHASE1_PHASE2

  3. Sep 2021 — Mar 2022 [monthly]

    Recruiting PHASE1_PHASE2

  4. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE1_PHASE2

  5. Jan 2021 — Jun 2021 [monthly]

    Recruiting PHASE1_PHASE2

  6. Jun 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  7. Mar 2020 — Jun 2020 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Ascentage Pharma Group Inc.
Data source: Ascentage Pharma Group Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations